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Abstract
Mice overexpressing human alpha-synuclein in oligodendrocytes (MBP1-a-
syn) recapitulate some key functional and neuropathological features of multi-
ple system atrophy (MSA). Whether or not these mice develop severe auto-
nomic failure, which is a key feature of human MSA, remains unknown. We
explored cardiovascular autonomic regulation using long-term blood pressure
(BP) radiotelemetry and pharmacological testing. We instrumented 12 MBP1-
a-syn mice and 11 wild-type mice aged 9 months for radiotelemetry. Animals
were tested with atropine, metoprolol, clonidine, and trimethaphan at 9 and
12 months age. We applied spectral and cross-spectral analysis to assess heart
rate (HR) and BP variability. At 9 months of age daytime BP (transgenic:
101  2 vs. wild type: 99  2 mmHg) and HR (497  11 vs. 505  16 beats/
min) were similar. Circadian BP and HR rhythms were maintained. Nighttime
BP (109  2 vs. 108  2 mmHg) and HR (575  15 vs. 569  14 beats/min),
mean arterial BP responses to trimethaphan (21  8 vs. 10  5 mmHg,
P = 0.240) and to clonidine (8  3 vs. 5  2 mmHg, P = 0.314) were sim-
ilar. HR responses to atropine (+159  24 vs. +146  22 beats/min), and to
clonidine (188  21 vs. 163  33 beats/min) did not differ between strains.
Baroreflex sensitivity (4  1 vs. 4  1 msec/mmHg) and HR variability (total
power, 84  17 vs. 65  21 msec²) were similar under resting conditions and
during pharmacological testing. Repeated measurements at 12 months of age
provided similar results. In mice, moderate overexpression of human alpha-
synuclein in oligodendrocytes is not sufficient to induce overt autonomic
failure. Additional mechanisms may be required to express the autonomic
failure phenotype including higher levels of expression or more advanced age.
Introduction
Multiple system atrophy (MSA) is a rare neurodegenera-
tive disorder characterized by Parkinsonism poorly
responding to levodopa, cerebellar ataxia, and autonomic
failure in any combination (Kaufmann and Biaggioni
2003; Flabeau et al. 2010). Autonomic failure with severe
orthostatic and postprandial hypotension is a disabling
feature in many MSA patients (Kaufmann and Biaggioni
2003). MSA patients with autonomic failure are
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commonly hypertensive in the supine position such that
the diurnal blood pressure profile is reversed. The pecu-
liar clinical presentation results from complex abnormali-
ties in sympathetic nervous system control through
baroreflex mechanisms. Supine plasma norepinephrine
concentrations and cardiac adrenergic terminals in tho-
racic 6-[(18)F]fluorodopamine PET studies are within the
normal range in MSA patients, suggesting that efferent
sympathetic nerves are at least in part preserved (Sharabi
et al. 2006). Therefore, pharmacological sympathetic inhi-
bition lowers blood pressure more in MSA patients than
in healthy subjects (Sharabi et al. 2006). However, sympa-
thetic efferents are disconnected from central nervous sys-
tem input without baroreflex feedback control.
Symptomatic management of MSA-associated autonomic
failure remains disappointing and curative treatments do
not exist. Identification of alpha-synuclein containing glial
cytoplasmic inclusions could provide a treatment target.
Alpha-synuclein, a 140 amino acid synaptic protein, is
involved in the pathogenesis of MSA (Kaufmann and Bia-
ggioni 2003; Ubhi et al. 2011). Neuropathologically, defi-
nite human MSA is characterized by the presence of
misfolded alpha-synuclein in oligodendroglial cells (Gil-
man et al. 2008). Transgenic and toxic animal models
have been developed to assess candidate drugs for MSA
treatment (Polinsky 1984; Robertson et al. 2001; Ubhi
et al. 2008; Stefanova et al. 2009; Stemberger et al. 2011).
Mice overexpressing human alpha-synuclein in oligoden-
drocytes recapitulate key functional and neuropathological
features of MSA (Shults et al. 2005; Stefanova et al. 2005;
Rockenstein et al. 2007). Whether or not these mice
model MSA abnormalities in cardiovascular autonomic
regulation is unknown. Therefore, we explored cardiovas-
cular autonomic regulation using long-term blood pres-
sure radiotelemetry combined with detailed
pharmacological testing.
Materials and Methods
Animals
We obtained transgenic mice overexpressing human
alpha-synuclein under the control of the oligodendrocyte-
specific murine myelin basic protein promoter (MBP1-a-
syn) from the Experimental Neuropath Laboratory,
Department of Neurosciences, University of California,
San Diego, La Jolla, CA. Mice had free access to standard
chow (0.25% sodium, SNIFF Spezialit€aten GmbH, Soest,
Germany) and drinking water. They were maintained on
a 12-h light/12-h dark cycle with light on at 6:00 AM. The
protocol was approved by the local council on animal
care of the Max Delbrueck Center for Molecular Medi-
cine, Berlin-Buch, Germany, that corresponds to require-
ments of the American Physiological Society.
Telemetry
We instrumented 12 MBP1-a-syn transgenic and 11 wild-
type mice aged 9 months for radiotelemetry (TA11PA-
C20, Data Sciences International, St. Paul, MN) to follow
blood pressure and heart rate changes continuously over
time. The telemetric techniques and the approaches
employed to analyze autonomic cardiovascular regulation
are described in detail elsewhere (Gross et al. 2008).
Briefly, we anesthetized mice by isoflurane (CuraMed
Pharma GmbH, Karlsruhe, Germany). Then, we advanced
the pressure-sensing catheter through the right femoral
artery into the abdominal aorta and placed the transmit-
ter in a subcutaneous pocket along the right flank. Mice
recovered 10 days before baseline blood pressure and
heart rate values were recorded. By this time, the mice
had regained their circadian blood pressure and heart rate
rhythm, and surgery and anesthesia-induced changes in
systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial pressure (MAP), and HR had
abated.
Data were sampled every 5 min for 10 sec continuously
day and night with a sampling rate of 1000 Hz and stored
on a hard disk. SBP, DBP, and HR were recorded using
the DATAQUEST software (A.R.T. 2.1, Data Sciences
International). Continuous beat-by-beat values of blood
pressure and heart rate were recorded during morning
hours for spectral analysis and pharmacological testing.
Heart rate was computed from the pulse intervals of the
blood pressure recordings.
Pharmacological testing
At 9 and 12 months of age, we tested the same mice with
atropine sulfate (2 mg/kg), metoprolol (4 mg/kg), cloni-
dine (1 mg/kg), and trimethaphan (40 mg/kg). We dis-
solved all substances in 0.9% NaCl (10 ll/g body weight)
for intraperitoneal injection. Following injection, we
returned mice to their cages and continued beat-by-beat
blood pressure and heart rate recordings. Baseline values
were obtained from 1 h recording before i.p. injections.
The peak changes in BP and HR in response to each dose
of vasoactive drugs were calculated by taking 10-min
average at the individual nadir response and expressing
this as change relative to the 1-h baseline prior to admin-
istration. The first minutes after returning the mice to the
cage were excluded from analysis to avoid the influence
of the initial stress. Beat-by-beat BP and HR values were
derived from these 1-h continuously recorded data (Gross
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et al. 2008). Mice recovered at least 24 h before we tested
the next drug.
Heart rate- and blood pressure variability
We applied spectral and cross-spectral analysis to assess
heart rate variability, blood pressure variability, and baro-
reflex sensitivity as described previously (Gross et al.
2008). Briefly, beat-to-beat values of detected pulse inter-
vals and BP values were interpolated, low-pass filtered
(cutoff 6 Hz), and resampled at 12 Hz. We used 49-sec
data segments for spectral analysis. Linear trends were
removed and power spectral density was estimated with
the FFT-based Welch algorithm using segments of 512
data points with 50% overlapping and Hanning window.
The power in the frequency range of low frequencies (LF:
0.25–1.0 Hz) and high frequencies (HF: 1.0–6.0 Hz) were
calculated. Five representative intervals were chosen for
spectral analysis and averaged during 1-h baseline and at
maximum drug response. We calculated spontaneous
baroreflex slope as the slope of the linear regression line
between systolic BP and the subsequent pulse intervals
using sequences defined as episodes of at least three heart
beats associated with an increase in SBP per beat. Cross-
spectral baroreflex gain was defined as the mean magni-
tude value of transfer function between systolic BP and
pulse interval in the low-frequency band (BRS-LF). The
data analysis was performed with the PV-wave software
(Visual Numerics, Houston, TX).
Histochemistry
Transgenic and wild-type mice were sacrificed, whole
brains were removed, and perfused overnight with 4%
paraformaldehyde in PBS pH 7.4, then cryoprotected in
30% saccharose for 24–48 h at 4°C, until the brain sunk
to bottom of the container. Brain sections (50 lm) were
cut on a cryostat at 20°C and transferred into cold
phosphate-buffered saline (PBS). The free-floating brain
sections were incubated in PBST (PBS-0.5% Triton X-
100) for 30 min at room temperature, blocked with 10%
normal donkey serum in PBST for 1 h at room tempera-
ture, and incubated in 1:200 rabbit polyclonal antihuman
a-synuclein antibody (Millipore-Chemicon, Temecula,
CA) at 4°C overnight. Sections were then rinsed with
PBS, incubated with secondary antibodies, donkey anti-
rabbit Cy3 conjugated (Invitrogen, Carlsbad, CA) for 2 h
at room temperature, and rinsed again in PBS. Free-float-
ing sections were then carefully placed on slides and
mounted with Vectashield containing DAPI (Vector Labs.
AXXORA, L€orrach, Germany) and imaged under Zeiss
Axioplan microscope in order to verify the overexpression
of human a-synuclein. To locate and to count parasym-
pathetic preganglionic motor neurons in the nucleus
ambiguous serial vibratome sections from wild-type
(n = 6) and transgenic mice (n = 6, age 6 months) were
immunolabeled with the rabbit polyclonal antibody
against choline acetyltransferase (ChAT) and analyzed by
the dissector method with the MBL serology system
(Ubhi et al. 2013). Discrete groups of ChAT-positive cells
were identified and compared between strains.
Statistics
Data are presented as mean  SEM. Statistically signifi-
cant differences in mean values were evaluated by one-
way ANOVA followed by Bonferroni post hoc test. For
paired data, we used the nonparametric Wilcoxon signed-
rank test. A value of P < 0.05 was used to determine sta-
tistical significance.
Results
At 9 months of age daytime blood pressure (tg: 101  2
vs. wt: 99  2 mmHg) and heart rate (tg: 497  11 vs.
wt: 505  16 beats/min) were similar in MBP1-a-syn
mice and in wild-type mice. Circadian blood pressure and
heart rate rhythms were maintained in MBP1-a-syn mice.
Nighttime BP (tg: 109  2 vs. wt: 108  2 mmHg) and
HR (tg: 575  15 vs. wt: 569  14 beats/min) were simi-
lar in both strains. Similar results were obtained at
12 months of age. Circadian variations in blood pressure
and heart rate measured over 3 days for transgenic
MBP1-a-syn and wild-type mice at 9 and 12 months of
age are illustrated in Figure 1 together with immunohis-
tochemical staining of alpha-synuclein in the brain of
wild-type and transgenic mice (bottom).
Transgenic MBP1-a-syn showed a trend of reduced
ChAT-positive cells in the nucleus ambiguous compared
to wild-type mice (Fig. 2, P = 0.1028). Mean arterial
blood pressure responses to trimethaphan (tg: 21  8
vs. wt: 10  5 mmHg, P = 0.240) and to clonidine (tg:
8  3 vs. wt: 5  2 mmHg, P = 0.314) were similar
in both strains. HR responses to trimethaphan (tg:
90  25 vs. wt: 98  22 beats/min), and to clonidine
(tg: 188  21 vs. wt: 163  33 beats/min) did not
differ between strains. Figure 3 shows the BP and HR val-
ues measured for 1 h immediately after the drug injection
during pharmacological testing at 9 months of age. We
obtained similar results during pharmacological testing at
9 and 12 months of age. The time courses of BP and HR
responses were almost identical in both strains.
Figure 4 illustrates individual BP responses to trimetha-
phan and clonidine compared to baseline in transgenic
and in wild-type mice. These responses did not signifi-
cantly differ between strains. Numerically, transgenic ani-
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mals tended to have a more pronounced depressor
response. However, the difference between groups was
rather small and much less than in human MSA.
Baroreflex sensitivity (BRS-LF, tg: 4  1 vs. wt:
4  1 msec/mmHg) and HR variability (total power, tg:
84  17 vs. wt: 65  21 msec²) were similar under rest-
ing conditions and during pharmacological testing. Fig-
ure 5 illustrates changes in HR, HR variability, and
baroreflex sensitivity in response to atropine. A similar
increase in HR after atropine (tg: +159  24 vs. wt:
+146  22 beats/min) was accompanied by similar
decreases in HR variability in the time and frequency
domains. Moreover, BP variability in the low-frequency
band increased by the same amount in both strains. Baro-
reflex sensitivity measured with the cross-spectral method
in the low-frequency range as well as with the sequence
Figure 1. Circadian variations in heart rate (HR, top-left) and mean arterial blood pressure (MAP, top-right) measured over 3 days in MBP1-a-
syn (tg) mice (transgenic) and in wild-type mice (wild type) at 9 and 12 months of age. Distribution of alpha-synuclein in MBP1-a-syn tg mice
(bottom). The sagittal vibratome section is immunolabeled with an antibody against alpha-synuclein (rabbit polyclonal from Millipore) illustrating
the distribution of the alpha-synuclein aggregates in oligodendroglial cells in various cortical and subcortical brain regions. Of the subcortical
regions affected included those involved in hemodynamical regulation such as rostral ventrolateral medulla (RVLM), nucleus tractus solitarius
(NTS), and dorsal vagus nucleus (DVN). The inset displays the alpha-synuclein aggregates in oligodendroglial cells in the MBP1-a-syn mice as
compared to a wild-type control. Bar = 250 µm for the low power image and 10 µm for the inset.
A B
Figure 2. ChAT immunoreactivity in the nucleus ambiguus of nontransgenic and MBP1-a-syn tg mice (A). Serial vibratome sections from wild-
type (n = 6) and MBP1-a-syn tg mice (n = 6) were immunolabeled with the rabbit polyclonal antibody against ChAT and analyzed by the
dissector method with the MBL serology system. Discrete groups of ChAT-positive cells were identified, in both groups, compared to wild type
the MBP1-a-syn tg mice showed a nonsignificant trend (B). Bar = 25 µm.
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technique was reduced by the same amount in both
strains. Pharmacological testing at 12 months of age pro-
vided similar results.
Discussion
The main finding of our study is that heart rate and
blood pressure regulation in adult transgenic mice overex-
pressing at moderate levels human alpha-synuclein in oli-
godendrocytes is not severely impaired compared to wild-
type mice. In particular, we observed no abnormalities in
the diurnal blood pressure profile or heart rate and blood
pressure responses to pharmacological testing at 9 and
12 months of age. Finally, heart rate variability, blood
pressure variability, and baroreflex sensitivity were also
intact in transgenic animals.
Use of a well-characterized transgenic mouse model
expressing human alpha-synuclein under the control of
the murine myelin basic protein promoter is a strength of
our study (Shults et al. 2005). Several lines expressing low,
intermediate, and high levels of alpha-synuclein were
developed. Expression of moderate levels of alpha-synuc-
lein (line 1) under the murine myelin basic protein pro-
moter resulted in the formation of aggregates in
oligodendrocytes in cortical and subcortical regions and
was associated with axonal loss and mild behavioral motor
deficits. Mice expressing high alpha-synuclein levels (line
29) exhibited severe neurological symptoms including
tremors, ataxia, and seizure activity and died prematurely
(Shults et al. 2005). In similar recently developed trans-
genic animal models, alpha-synuclein expression in oligo-
dendrocytes was driven by the 2,’ 30-cyclic nucleotide 30-
phosphodiesterase (CNP) (Yazawa et al. 2005) or the pro-
teolipid protein promoter (PLP) (Kahle et al. 2002). Neu-
rodegeneration with alpha-synuclein overexpression in
oligodendrocytes included neural circuits governing auto-
nomic cardiovascular responses (Kahle et al. 2002). Alpha-
synuclein accumulation, neurodegeneration, and neuro-
logical symptoms appear to be particularly pronounced
when alpha-synuclein expression is driven by the murine
myelin basic protein promoter (Shults et al. 2005). Thus,
Figure 3. Heart rate (HR, bottom) and mean arterial pressure (MAP, top) after i.p. injection of 1 mg/kg clonidine (left) and after i.p. injection
of 40 mg/kg trimethaphan (right) in MBP1-a-syn and in wild-type mice at 9 months of age. The initial high absolute values after returning the
mice to the cage are caused by stress and were not used for analysis.
Figure 4. Individual BP changes in wild-type (wt) and in MBP1-a-
syn (tg) mice in response to trimethaphan (left) and clonidine
(right). Changes in BP and HR are expressed as change relative to
1-h baseline prior to drug administration.
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2014 | Vol. 2 | Iss. 11 | e12209
Page 5
J. Tank et al. Human Alpha-Synuclein and Autonomic Failure
our model was suitable assessing influences of alpha-syn-
uclein in oligodendrocytes on autonomic cardiovascular
regulation. We chose to analyze MBP1-a-syn line 1 mice
because they overexpress synuclein at moderate levels and
the mice have a normal life expand in contrast to higher
expresser lines that die prematurely precluding adequate
assessment of cardiovascular regulation. Another strength
of our study is the comprehensive assessment of cardio-
vascular autonomic function using physiological and phar-
macological methodologies over several months. Studies
using radiotelemetry monitoring in mice over several
months are rare. Long-term monitoring in older mice
allows to detect and to follow cardiovascular changes sec-
ondary to neurodegenerative processes over time.
We expected MBP1-a-syn mice to model cardiovascular
autonomic abnormalities typically observed in MSA
patients with autonomic failure. While orthostatic hypo-
tension cannot be assessed in mice, other MSA-associated
blood pressure abnormalities can be ascertained. Food
ingestion and exercise induce vasodilation in splanchnic
tract and working musculature, respectively. Because baro-
reflex-mediated increases in sympathetic activity cannot
compensate for the vasodilation in MSA patients, blood
pressure decreases profoundly (Sharabi et al. 2006). Since
mice are physically active and fed during the night, the
blood pressure profile should be profoundly altered in
MBP1-a-syn mice. Yet, wild-type and MBP1-a-syn mice
showed normal blood pressure increases during the active
phase and reductions during the resting phase. Due to loss
of baroreflex restraint, residual sympathetic activity drives
an increase in supine blood pressure in many MSA
patients. We did not observe an increase in blood pressure
Figure 5. Responses (D) of heart rate (HR), heart rate variability in the time domain (rmssd = root mean square of successive differences),
heart rate variability in the frequency domain (TP = total power, LF = power in the low-frequency range, HF = power in the high-frequency
range), systolic blood pressure variability in the low-frequency range (LFsys) and baroreflex sensitivity calculated by cross-spectral analysis (BRS-
LF) or by the sequence technique (BRS-up, BRS-down) to atropine (2 mg/kg) in MBP1-a-syn (tg) and in wild-type (wt) mice at 9 months of age.
2014 | Vol. 2 | Iss. 11 | e12209
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in MBP1-a-syn mice. Furthermore, the depressor response
to ganglionic blockade or clonidine was not excessive.
Together with normal blood pressure variability, heart rate
variability, and baroreflex sensitivity, our study excludes
that sympathetic efferents are disconnected from central
nervous input in MBP1-a-syn mice with moderate overex-
pression of human alpha-synuclein in oligodendrocytes.
The most likely explanation for our findings is that the
level of alpha-synuclein overexpression may not have been
sufficient to promote degeneration of subcortical struc-
tures involved in regulation of cardiovascular function.
The regulation of such functions depends on the rostral
ventrolateral medulla sending glutamatergic projections to
spinal sympathetic preganglionic neurons located in the
intermediolateral nucleus of the spinal cord. Hence, when
baroreceptors are activated through increased blood pres-
sure, the baroreflex afferents in the nucleus tractus solitari-
us (NTS) activate the caudal ventrolateral medulla neurons
(CVLM), which in turn restrain efferent sympathetic activ-
ity generated in the rostral ventrolateral medulla (RVLM),
thus lowering blood pressure. Moreover, these mice might
represent early stages of MSA prior to the development of
overt degenerative pathology. Yet, the observation that
parasympathetic heart rate regulation is altered in trans-
genic mice overexpressing human alpha-synuclein under
the control of the PLP promoter as well as the impaired
HR responses to BP lowering by nitroprusside (Fleming
et al. 2013) in MBP1-a-syn mice support the idea that
alpha-synuclein accumulation can affect cardiovascular
autonomic regulation (Kuzdas et al. 2013). The trend of
reduced ChAT-positive cells in the nucleus ambiguous, the
origin of vagal preganglionic neurons projecting directly to
the ganglia near the heart, may support this hypothesis. A
lower number of ChAT-positive cells may cause a reduced
vagal tone and a lesser response to atropine. However, the
reduction in ChAT-positive cells was not sufficient to
cause differences in the response to atropine in our study.
MBP1-a-syn mice express lower levels of synuclein com-
pared to the PLP tg mice. Mice driven by MBP promoter
at higher levels such as line MBP29 might display more
pronounced loss of ChAT-positive cells and related defi-
cits, this will be the focus of a follow-up study.
Another possible explanation for the absence of severe
sympathetic dysfunction in MBP1-a-syn mice is that
mice, in general, are difficult models for human auto-
nomic disease. Possibly, in murine model, subcortical cells
and RVLM are resistant to degeneration. In addition, dif-
ferent promoters may target different subtypes of oligo-
dendrocytes and may drive alpha-synuclein only in a
subset of oligodendroglial cells. Therefore, a model that is
most relevant to human degenerative patterns should be
selected for future studies, in order to develop effective
new therapeutic strategies.
We previously observed that in diabetic NOD mice,
diabetes produces sympathetic dysfunction while cardiac
vagal control and baroreflex sensitivity were preserved
(Gross et al. 2008). Diabetic patients exhibit opposite
changes in cardiovascular autonomic regulation with
vagal dysfunction preceding sympathetic dysfunction. Yet,
cardiovascular abnormalities in mice with isolated adren-
ergic dysfunction due to genetic dopamine-beta-hydroxy-
lase deletion resemble clinical abnormalities in patients
(Usera et al. 2004). Given the limited contribution of
vagal tone to resting cardiovascular regulation in mice
compared to human subjects, abnormalities in sympa-
thetic cardiovascular control may be easier to detect in
mouse models. Sympathetic dysfunction was the expected
abnormality in our study. Finally another possibility is
that time points beyond 9–12 months may be required to
trigger autonomic cardiovascular alterations.
We conclude that adult mice expressing moderate levels
of human alpha-synuclein under the control of the mur-
ine myelin basic protein promoter display preserved car-
diovascular sympathetic functioning. The observation
may suggest that moderate levels of alpha-synuclein over-
expression in oligodendrocytes may not be sufficient to
produce damage to subcortical structures involved in car-
diovascular regulation and that either higher levels of syn-
uclein or more advanced age is necessary. Indeed, in
mice, neurodegeneration is more pronounced when
alpha-synuclein overexpression is combined with deletion
of neuroprotective factors (Ubhi et al. 2010). Our find-
ings may be relevant for the development of animal mod-
els testing candidate drugs for MSA-associated
sympathetic dysfunction. Furthermore, our findings could
provide an impetus not to restrict the search for these
drugs to compounds interfering with alpha-synuclein
deposition in oligodendrocytes.
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